BMEZ 📈 BlackRock Health Sciences - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09260E1055
BMEZ: Biotech, Pharmaceuticals, Medical, Devices, Healthcare
Additional Sources for BMEZ Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BMEZ Stock Overview
| Market Cap in USD | 1,642m |
| GiC Sub-Industry | Health Care Services |
| IPO / Inception | 2020-01-29 |
BMEZ Stock Ratings
| Growth 5y | 7.45% |
| Fundamental | - |
| Dividend | 85.9% |
| Rel. Strength Industry | 171 |
| Analysts | - |
| Fair Price Momentum | 14.85 USD |
| Fair Price DCF | 26.70 USD |
BMEZ Dividends
| Dividend Yield 12m | 10.26% |
| Yield on Cost 5y | 11.41% |
| Annual Growth 5y | 15.16% |
| Payout Consistency | 97.3% |
BMEZ Growth Ratios
| Growth Correlation 3m | -0.8% |
| Growth Correlation 12m | 77.9% |
| Growth Correlation 5y | -28.1% |
| CAGR 5y | 2.20% |
| CAGR/Mean DD 5y | 0.09 |
| Sharpe Ratio 12m | 0.53 |
| Alpha | -14.02 |
| Beta | 0.99 |
| Volatility | 17.07% |
| Current Volume | 409.4k |
| Average Volume 20d | 437.4k |
What is the price of BMEZ stocks?
As of December 21, 2024, the stock is trading at USD 14.74 with a total of 409,400 shares traded.
Over the past week, the price has changed by -3.67%, over one month by -0.72%, over three months by -4.73% and over the past year by +13.93%.
As of December 21, 2024, the stock is trading at USD 14.74 with a total of 409,400 shares traded.
Over the past week, the price has changed by -3.67%, over one month by -0.72%, over three months by -4.73% and over the past year by +13.93%.
Is BlackRock Health Sciences a good stock to buy?
Neither. Based on ValueRay Analyses, BlackRock Health Sciences is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 7.45 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BMEZ as of December 2024 is 14.85. This means that BMEZ is currently overvalued and has a potential downside of 0.75%.
Neither. Based on ValueRay Analyses, BlackRock Health Sciences is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 7.45 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BMEZ as of December 2024 is 14.85. This means that BMEZ is currently overvalued and has a potential downside of 0.75%.
Is BMEZ a buy, sell or hold?
BlackRock Health Sciences has no consensus analysts rating.
BlackRock Health Sciences has no consensus analysts rating.
What are the forecast for BMEZ stock price target?
According to ValueRays Forecast Model, BMEZ BlackRock Health Sciences will be worth about 16.5 in December 2025. The stock is currently trading at 14.74. This means that the stock has a potential upside of +11.94%.
According to ValueRays Forecast Model, BMEZ BlackRock Health Sciences will be worth about 16.5 in December 2025. The stock is currently trading at 14.74. This means that the stock has a potential upside of +11.94%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 16.5 | 11.9% |